scispace - formally typeset
Search or ask a question

Showing papers by "Hatice Hasturk published in 2005"


Journal ArticleDOI
TL;DR: The lower expression of CD38 in neutrophils may be related to altered neutrophil function in LAgP, and the decrease was positively correlated with the defect in chemotactic migration to fMLP.
Abstract: Background: Localized aggressive periodontitis (LAgP) is associated with neutrophil dysfunction including decreased chemotaxis and reduced calcium entry. It has been suggested that CD38 is involved in chemotaxis. Little is known, however, about the relationship of CD38 and LAgP patients. In this study, we focused on the level of CD38 expression between LAgP and normal subjects and examined the involvement of CD38 in abnormal neutrophil chemotaxis of LAgP patients. Methods: Neutrophils from 12 normal subjects and 12 LAgP patients were isolated from peripheral venous blood. Membrane associated proteins were extracted from cells with or without N-formylmethionine leucyl-phenylalanine (fMLP) stimulation. CD38 expression was measured using Western blotting. Band density was measured using an imaging densitometer. Results: There was no statistical difference between normal subjects and LAgP patients in resting CD38 expression (basal level). However, the fMLP-stimulated neutrophils exhibited a significant decrease of CD38 expression in LAgP subjects compared to normal subjects. The decrease of CD38 was positively correlated with the defect in chemotactic migration to fMLP. Conclusion: These data suggest that the lower expression of CD38 in neutrophils may be related to altered neutrophil function in LAgP.

17 citations


Journal ArticleDOI
TL;DR: Findings indicate that certain early stimulus responses are aberrant in LAP‐PMN, that internal redistribution of cytoplasmic‐free calcium is compromised, and, additionally, that a membrane‐associated Ca2+ transport defect may be present.
Abstract: In view of the reports that polymorpho- nuclear leukocytes (PMN) of patients with localized aggressive periodontitis (LAP) exhibit hyper-re- sponsiveness to stimulation, it has been suggested that such abnormalities could lead to PMN-medi- ated tissue damage during inflammation. To deter- mine whether these abnormalities include signal transduction, we compared cytoplasmic calcium concentration ((Ca 2 )i) and cytoplasmic pH (pH i ) changes, early stimulus responses to chemo- tactic agents, of LAP versus control (C)-PMN and explored whether these could be modulated by sensitizing cytokines or calcium channel-blocking agents. PMN responses of LAP patients were compared with age- and gender-matched con- trols. (Ca 2 )i and pHi were measured fluori- metrically using 1H-indole-6-carboxylic acid, 2-(4-(bis(2-((acetyloxy)methoxy)-2-oxoethyl)- amino)-3-(2-(2-(bis(2-((acetyloxy)methoxy)-2- oxoethyl)amino)-5-methylphenoxy)ethoxy)phenyl)-1 and 2,7-bis-(carboxyethyl)-5(6)-carboxyfluores- cein as respective probes. Not only was the maxi- mal calcium response to chemoattractants higher in LAP-PMN, but also their subsequent intracellu- lar calcium redistribution was significantly slower. The slower calcium redistribution of LAP-PMN, but not their higher maximal calcium response, was successfully mimicked in C-PMN treated with Nifedipine™ or 1-(b-(3-(4-methoxyphenyl)propoxy)- 4-methoxyphenethyl)-1H-imidazole-HCl, both known to be inhibitors of membrane-associated calcium influx, but this redistribution was not af- fected when inhibitors of other calcium influx mechanisms, Diltiazem™ or Verapamil™, were used. Taken together, our findings indicate that certain early stimulus responses are aberrant in LAP-PMN, that internal redistribution of cytoplas- mic-free calcium is compromised, and, addition- ally, that a membrane-associated Ca 2 transport defect may be present. J. Leukoc. Biol. 78: 612-619; 2005.

14 citations


Journal ArticleDOI
TL;DR: Neutrophil apoptosis provides a signal to monocytes, changing the phenotype of the monocyte resulting in the production of anti-inflammatory cytokines and suppression of proinflammatory cytokine generation from monocytes in response to lipopolysaccharide.
Abstract: Background: Neutrophil apoptosis may play a critical role in the resolution of inflammation by stimulating anti-inflammatory cytokine generation from monocytes. In this study, we investigated the effect of apoptotic neutrophils on interleukin (IL)-10 and IL-1β production from monocytes in response to Porphyromonas gingivalis lipopolysaccharide. Methods: Peripheral blood neutrophils from healthy individuals were isolated by sodium diatrizoate density gradient centrifugation. In order to induce apoptosis, neutrophils were cultured for 24 hours in modified Dulbecco's medium supplemented with 10% autologous serum. Cell apoptosis was quantified by Annexin V positivity and loss of CD16 expression on the cell surface. Peripheral blood mononuclear cells were isolated from the same subjects; monocytes were purified by magnetic cell sorting and cultured with or without apoptotic or fresh neutrophils. Lipopolysaccharide from Porphyromonas gingivalis was used for cell stimulation. IL-1β and IL-10 levels in supernatants were determined by enzyme-linked immunosorbent assay (ELISA). Results: IL-10 generation was significantly increased in monocytes cultured with apoptotic neutrophils compared to monocytes alone or cocultured with fresh neutrophils (P <0.05). IL-1β was suppressed both in resting and lipopolysaccharide-stimulated monocytes in the presence of apoptotic neutrophils compared to monocytes alone or monocytes cultured with fresh neutrophils at all time points (P <0.05). Conclusion: Neutrophil apoptosis provides a signal to monocytes, changing the phenotype of the monocyte resulting in the production of anti-inflammatory cytokines and suppression of proinflammatory cytokines in response to lipopolysaccharide. J Periodontol 2005;76:964-971.

12 citations


Patent
20 Dec 2005
TL;DR: In this article, the authors provide improved systems and methods for the local delivery of H2 antagonists, such as topical administration of an effective amount of a H2 antagonist encapsulated in liposomes.
Abstract: The present invention provides improved systems and methods for the local delivery of H2 antagonists. The inventive methods include topical administration of an effective amount of a H2 antagonist encapsulated in liposomes. In certain embodiments, the H2 antagonist, for example, Cimetidine, is encapsulated into paucilamellar liposomes, such as NOVASOME® microvesicles. Also provided are pharmaceutical compositions comprising liposome-encapsulated H2 antagonists. The methods and compositions of the present invention may be used to treat any disease state or condition where local administration of H2 antagonists is beneficial.

8 citations